A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin
Fig 4
The effects of LLL12B, cisplatin, paclitaxel, and drug combination on cell migration.
Wound-healing assays were performed to evaluate the migration ability of SKOV3 and A2780 ovarian cancer cells. SKOV3 and A2780 cells were seeded in 6-well plates and treated with DMSO or different concentration of drugs: LLL12B or cisplatin or paclitaxel or the combination. The differences were found to be significantly different at ***p<0.001 and ****p<0.0001.